

POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Collins *et al.*

Confirmation No.: 4775

Serial No.: 10/654,112

Art Unit: 1626

Filed: September 2, 2003

Examiner: Ebenezer O. Sackey

For: MODULATION OF CCR4
FUNCTION

Attorney Docket No.: 11134-065-999

REVOCATION AND POWER OF ATTORNEYCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

ChemoCentryx, Inc. (assignee) hereby revokes any and all previous powers and appoints:

☒ Practitioners of Jones Day at Customer Number 20583

to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.


Please direct all correspondence address for the above-identified application to:

☒ The above mentioned Customer Number.☒ Firm or Individual Name:Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 901-9028

ChemoCentryx, Inc. is the:

☐ Applicant/Inventor☒ Assignee of record of the entire interest. See 37 CFR 3.71.
(Statement under 37 CFR 3.73(b) is applicable)

SIGNATURE of Applicant or Assignee of Record			
Date:	11/29/06	Signature:	
		Typed Name:	Thomas J. Schall
		Position/Title:	President & CEO

Statement Under 37 C.F.R. 3.73(b)

ChemoCentryx, Inc. states that it is:

- ☒ the assignee of the entire right, title, and interest; or
☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is %

in the patent application/patent identified above by virtue of:


- ☒ An assignment from the inventors Brian B. McMaster, Daniel J. Dairaghi and Thomas J. Schall of the patent application U.S. App. No. 09/975,566 filed October 11, 2001, from which the above-identified patent application is a divisional application. A copy of the assignment thereof is attached.
- ☐ Additional documents in the chain of title are listed on a supplemental sheet.
- ☒ Copies of assignments or other documents in the chain of title are attached.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: ChemoCentryx, Inc.

129/06

Signature:



Typed Name:

Thomas J. Schall

Position/Title:

President & CEO

req. of all the inventors or assignees of record of the entire interest or their representative(s) are
multiple forms if more than one signature is required.

☒ To

forms are submitted.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Collins *et al.*

Docket No.: 11134-065-999

Serial No. 10/654,112

Group Art Unit: 1626

Filed: September 2, 2003

Examiner: Ebenezer O. Sackey

For: MODULATION OF CCR4 FUNCTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. 3.73(b)

Amgen Inc. (hereinafter "Amgen"), a corporation of the State of Delaware having a place of business at One Amgen Center Drive, Thousand Oaks, California, 91320, is the assignee of the entire right, title, and interest in the above-identified U.S. patent application, which is a divisional of U.S. Application No. 09/975,566 filed October 11, 2001. A chain of title from the inventors of the above-identified application to Amgen Inc. is shown below.

1. From inventors Tassie Collins, Hossen Mahmud, Julio Medina, Feng Xu, and Xuemei Wang To: Tularik, Inc. the assignment recorded November 25, 2002, in the USPTO at Reel 013520, Frame 0300.
2. From Tularik, Inc. To: Arrow Acquisition, LLC the merger recorded June 7, 2005, in the USPTO at Reel 016309, Frame 0003.
3. From Arrow Acquisition, LLC To: Amgen SF, LLC the change in name recorded June 7, 2005, in the USPTO at Reel 016309, Frame 0812.
4. From Amgen SF, LLC To: Amgen Inc. the assignment a copy of which is attached herewith.

The undersigned, whose title is supplied below, is empowered to sign this statement on behalf of Amgen.

**REVOCATION OR PREVIOUS POWER OF ATTORNEY AND
NEW POWER OF ATTORNEY BY ASSIGNEE**

Amgen hereby revokes all previous powers of attorney given in the above-identified application and hereby appoints the registered practitioners at Customer Number **20583** to prosecute this application, to make and to transact all business in the Patent and Trademark Office connected therewith.

REQUEST FOR CHANGE OF CORRESPONDENCE ADDRESS

Please send all future correspondence and direct telephone calls to Customer Number **20583**.

Respectfully submitted,

Date November 27, 2006

By: Stuart L. Watt
Stuart L. Watt
Vice President, Law
AMGEN Inc.